ARS Pharmaceuticals, Inc. Q1 FY2026 Earnings Call

ARS Pharmaceuticals, Inc. (SPRY)

Earnings Call FY2026 Q1 Call date: 2026-05-15 Concluded

Quarter scorecard

Revenue

$22.68M

+184.5% YoY

Diluted EPS

$-0.61

Net income

-$60.62M

Product $17.45M

+124.8%

Revenue Under Supply Agreements $2.74M

Revenue Under Collaboration Agreements $2.49M

+1085.2%